Overview
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analogue of human insulin-like growth factor 1 (IGF-1) engineered with two modifications relative to native IGF-1: a substitution of arginine for glutamic acid at the third amino acid position (the "R3" designation) and a 13-amino-acid extension ("Long") added to the N-terminus of the B-domain. These modifications were originally developed for laboratory and cell-culture research purposes to reduce binding affinity to IGF-binding proteins (IGFBPs), which normally sequester native IGF-1 in circulation and limit its bioavailability.
The foundational biochemistry describing the LR3 modification itself — including the work of Francis GL and colleagues characterising Long R3 IGF-1's reduced IGFBP binding and extended in vitro bioactivity — is real, published cell-culture and biochemistry research. However, this original research was conducted for use as a laboratory reagent in cell culture systems, not as a human injectable research or performance compound. Its subsequent adoption in bodybuilding and performance-enhancement communities as an injectable "research peptide" is a separate development with a much thinner in vivo human evidence base. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT |
✗ (no controlled human trials of injectable IGF-1 LR3 for anabolic/hypertrophy use identified) |
| Observational |
✗ |
| Animal Studies |
✔ (limited) |
| In Vitro |
✔ (extensive — this is where the core LR3 biochemistry literature exists) |
| Regulatory Approval |
✗ |
Mechanism of Action
Native IGF-1 signals through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates downstream PI3K/Akt and MAPK/ERK signalling cascades associated with cell growth, proliferation and anabolic metabolism, including protein synthesis in skeletal muscle. In normal physiology, the vast majority of circulating IGF-1 is bound to IGF-binding proteins (particularly IGFBP-3), which regulate its bioavailability and prevent excessive receptor activation.
The LR3 modification was specifically engineered to reduce binding affinity to IGFBPs by roughly 100-fold compared to native IGF-1, as characterised in the founding in vitro work by Francis GL et al. This means a greater proportion of administered IGF-1 LR3 remains "free" and available to bind IGF-1 receptors rather than being sequestered by binding proteins, and the added N-terminal extension also confers resistance to enzymatic cleavage, extending its functional half-life relative to native IGF-1. In research and grey-market use contexts, this is the basis for claims of stronger and more sustained anabolic/mitogenic signalling compared to native IGF-1 or recombinant human growth hormone-driven endogenous IGF-1 production. It's important to note the mitogenic (cell-proliferation-promoting) properties of unbound IGF-1 signalling are also the basis for long-standing theoretical safety concerns regarding unregulated cell growth, discussed further below.
Research Areas & Reported Effects
Reduced IGFBP Binding and Extended Bioactivity (In Vitro)
The core published research on the LR3 modification demonstrates its markedly reduced binding to IGFBPs and correspondingly prolonged bioactivity in cell culture systems compared to native IGF-1, forming the biochemical basis cited for its use as a research reagent and, subsequently, as a grey-market research compound.
Muscle Hypertrophy Research (Limited Animal Data)
Some animal studies have examined local or systemic IGF-1 analogue administration in relation to skeletal muscle hypertrophy and satellite cell activity. However, studies using the specific LR3 analogue in vivo for hypertrophy endpoints are limited relative to the volume of in vitro biochemistry literature, and no controlled human hypertrophy trials of injectable IGF-1 LR3 have been published.
Anecdotal Bodybuilding and Performance Use
The majority of real-world discussion of IGF-1 LR3 dosing, cycling and effects exists within online bodybuilding and performance-enhancement communities rather than peer-reviewed literature. These reports are not independently verified and carry substantial reporting bias; they should not be treated as research-grade evidence.
Research Data Summary
| Study / Model |
Reported Effect |
| In vitro IGFBP-binding assays (Francis GL et al.) |
Approximately 100-fold reduced binding affinity to IGFBP-3 compared to native IGF-1, resulting in prolonged free bioactivity in culture systems. |
| Cell proliferation assays (various cell lines, in vitro) |
Enhanced and more sustained mitogenic signalling relative to native IGF-1 at equivalent concentrations, attributed to reduced IGFBP sequestration. |
| Animal muscle/satellite cell studies (IGF-1 analogues generally) |
Some evidence of increased satellite cell activity and local hypertrophic signalling with IGF-1 pathway activation in rodent models; not all studies used the LR3-specific analogue. |
| Controlled human trials of injectable IGF-1 LR3 for hypertrophy |
Not identified in peer-reviewed literature at time of writing. |
Stack Combinations Studied
No peer-reviewed controlled research examines IGF-1 LR3 in combination with other peptides. Grey-market and community sources frequently describe pairing IGF-1 LR3 with growth hormone secretagogues (such as Ipamorelin or CJC-1295) or with PEG-MGF, on the theory of complementary anabolic pathway activation, but these combinations have not been studied in controlled settings and are not supported by published research data.
⚠️ No verified stack research exists for this compound. This section is intentionally left without fabricated combinations.
Research Protocol Reference
experimental research protocols only — not dosing recommendations. No peer-reviewed human dosing protocol exists for injectable IGF-1 LR3; figures circulating in non-scientific sources are not independently verified.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| In Vitro Cell Culture Protocol (research reagent use) |
Nanomolar range concentrations reported in published cell-culture assays |
Hours to days (culture duration) |
Single or repeated exposure per assay design |
IGFBP-binding and mitogenic signalling assays; not applicable to human dosing. |
| Human injectable protocol |
Not established in peer-reviewed literature |
Not established in peer-reviewed literature |
Not established in peer-reviewed literature |
Community-reported dosing exists but is not derived from controlled research and is not reproduced here. |
Observed Side Effects in Research
- No formal, peer-reviewed human safety or tolerability data exists for injectable IGF-1 LR3 in anabolic/performance use contexts
- Theoretical concerns exist regarding IGF-1 pathway activation and unregulated cell proliferation signalling, given IGF-1's known mitogenic properties, though this has not been specifically quantified for LR3 in controlled human studies
- Hypoglycaemia is a mechanistically plausible risk given IGF-1's structural and receptor overlap with insulin, and is frequently reported anecdotally in community sources, though not formally studied
- Community-reported effects (injection site reactions, organ growth concerns) are unverified self-reports, not peer-reviewed findings
Because no controlled human studies of injectable IGF-1 LR3 exist, a scientifically valid side-effect profile cannot be provided for this use context. The theoretical mitogenic and hypoglycaemic risk mechanisms are biologically plausible based on IGF-1 pathway biology, but have not been formally quantified for this specific analogue in this specific use case.
Compound Data
- CAS Number
- Not consistently assigned in public chemical registries for the LR3 analogue at time of writing
- Molecular Formula
- Not consistently published across secondary sources; refer to primary biochemistry literature (Francis GL et al.) for structural characterisation
- Molecular Weight
- Approximately 9,117 Da (commonly cited figure for the 83-amino-acid Long R3 IGF-1 sequence; not independently re-verified for this guide)
- Half-Life
- Extended relative to native IGF-1 due to reduced IGFBP binding; specific human in vivo half-life not established in peer-reviewed literature for injectable use
- Synonyms
- Long R3 IGF-1, LR3-IGF-1, Long R3
- Research Classification
- Synthetic IGF-1 analogue (modified B-domain extension + R3 substitution), originally a cell-culture research reagent
Scientific References
Note on evidence base: The core biochemistry of the LR3 modification (reduced IGFBP binding, extended in vitro bioactivity) is genuinely well-published, peer-reviewed science. However, this research was conducted using cell-culture systems as a laboratory reagent, not as a human injectable compound for anabolic or hypertrophy purposes. There is a meaningful gap between the established in vitro biochemistry and the largely anecdotal in vivo human use context — this guide keeps those two evidence bases clearly distinguished.
- [Francis GL et al. 1992] — Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. — Journal of Molecular Endocrinology — [In vitro]
- [Tomas FM et al. 1993] — Insulin-like growth factor (IGF)-I and especially IGF-I variants are anabolic in dexamethasone-treated rats. — Biochemical Journal — [Animal]
- [Clemmons DR 1998] — Role of insulin-like growth factor binding proteins in controlling IGF actions. — Molecular and Cellular Endocrinology — [Review, mechanistic background]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*